Factor H binding protein variants and methods of use thereof
View Patent ↗Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis , compositions comprising such proteins, and methods of use of such proteins, are provided.
1. A variant of factor H binding protein (fHbp), wherein the variant comprises:
a substitution of the serine at position 223 (S223) with arginine (S223R),
wherein the numbering of the position S223 is based on the numbering of amino acid residues in SEQ ID NO:1 and wherein the variant comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:1.
2. The variant fHbp of claim 1 , wherein the variant fHbp further comprises an amino acid substitution selected from the group consisting of R41S and R41A.
3. The variant fHbp of claim 1 , wherein the variant comprises an amino acid sequence having at least 90% amino acid sequence identity to SEQ ID NO:1.
4. The variant fHbp of claim 1 , wherein the variant comprises an amino acid sequence having at least 95% amino acid sequence identity to SEQ ID NO:1.
5. The variant fHbp of claim 1 , wherein the variant fHbp differs from the sequence of SEQ ID NO: 1 by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids.
6. An immunogenic composition comprising:
a) the variant fHbp according to claim 1 ; and
b) a pharmaceutically acceptable excipient.
7. The immunogenic composition of claim 6 , wherein the variant fHbp is in a vesicle preparation prepared from a Neisseria meningitidis.
8. The immunogenic composition of claim 6 , further comprising Neisserial surface protein A.
9. The immunogenic composition of claim 8 , wherein the pharmaceutically acceptable excipient comprises an adjuvant.
10. The immunogenic composition of claim 9 , wherein the adjuvant is aluminum phosphate.
11. The immunogenic composition of claim 9 , wherein the adjuvant is aluminum hydroxide.
12. A method of eliciting an antibody response to Neisseria meningitidis in a mammal, the method comprising administering to the mammal an immunologically effective amount of the immunogenic composition of claim 6 .
13. The method of claim 12 , wherein the mammal is a human.
14. A method of eliciting an antibody response to Neisseria meningitidis in a mammal, the method comprising administering to the mammal an immunologically effective amount of the immunogenic composition of claim 7 .
15. The method of claim 14 , wherein the mammal is a human.
16. The variant fHbp of claim 1 , wherein the variant fHbp comprises the amino acid sequence set forth in SEQ ID NO:8.
17. The variant fHbp of claim 1 , wherein the variant fHbp comprises the amino acid sequence set forth in SEQ ID NO:17.